The growth in pharmacy benefit manager-negotiated rebates in Medicare Part D and commercial plans for leading insulin products in recent years underscores how much those concessions have influenced list price increases relative to government-mandated discounts and rebates, according to a new analysis published in JAMA Network Open.
The insulin category is an often-cited example of the disconnect between list and net prices in competitive and highly-rebated categories....







